A61K 40/4226
Epidermal growth factor [egf]
Official title: {Epidermal growth factor [EGF]}
A61K40/4226 (Epidermal growth factor [egf]) appears on 3 US grants and 16 published applications in this corpus.
Search patents in A61K- Granted patents
- 3
- Published applications
- 16
- Assignees
- 10
- Inventors
- 29
- Latest grant
- 1 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 0 | 1 |
| 2020 | 0 | 1 |
| 2021 | 1 | 0 |
| 2022 | 0 | 2 |
| 2023 | 0 | 1 |
| 2024 | 0 | 2 |
| 2025 | 2 | 2 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Cancer antigen targets and uses thereof1 Jul 2025US 12,345,712 B2Memorial Sloan Kettering Cancer Center
- Cancer antigen targets and uses thereof25 Mar 2025US 12,259,390 B2Memorial Sloan Kettering Cancer Center
- Cancer antigen targets and uses thereof7 Dec 2021US 11,193,938 B2Memorial Sloan Kettering Cancer Center
- Method to generate improving car-t cells19 Mar 2026US 2026/0077045 A1Centre National De La Recherche Scientifique
- Cancer antigen targets and uses thereof8 Jan 2026US 2026/0009797 A1Memorial Sloan Kettering Cancer Center
- Compositions and methods for epigenome editing to enhance t cell therapy19 Jun 2025US 2025/0197823 A1Duke University
- Methods and compositions for treating cancer29 May 2025US 2025/0170177 A1The Regents of the University of California
- Chimeric apoptotic signal targeting lymphocytes (tim-4 castl) and methods of making and using same6 Jun 2024US 2024/0182540 A1
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.